Literature DB >> 1036806

Low-dose heparin and deep-vein thrombosis after total hip replacement.

P M Mannucci, L E Citterio, N Panajotopoulos.   

Abstract

The effect of subcutaneous low-dose heparin on postoperative deep-vein thrombosis (D.V.T.) (diagnosed by the 125I-labelled fibrinogen test) has been investigated in a trial of 143 patients undergoing the operation of total hip replacement. Two randomized studies were carried out: in one the scanning for D.V.T. was carried out daily for 7 days postoperatively andin the other for 15 days. In both, the incidence of D.V.T. was significantly lower in the heparin-treated patients (P less than 0.005). Bilateral D.V.T. was also prevented (P less than 0.05), through the extension of D.V.T. to the distal veins of the thigh was not significantly reduced. Heparin treatment was, however, followed by a higher incidence of severe postoperative bleeding (P less than 0.02) and wound haematoma formation (P less than 0.005), and the postoperative haemoglobin was significantly lower than in the control group (P less than 0.005). A higher number of transfused blood units was also needed by the heparin treated patients (P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1036806

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

Review 1.  The postdischarge risk of venous thromboembolism after hip replacement. The role of prolonged prophylaxis.

Authors:  D Bergqvist
Journal:  Drugs       Date:  1996       Impact factor: 9.546

2.  The current status of low-dose heparin in the prophylaxis of thrombophlebitis and pulmonary embolism.

Authors:  V V Kakkar
Journal:  World J Surg       Date:  1978-01       Impact factor: 3.352

3.  Prophylaxis of venous thromboembolism: analysis of cost effectiveness.

Authors:  E W Salzman; G C Davies
Journal:  Ann Surg       Date:  1980-02       Impact factor: 12.969

4.  Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement.

Authors:  S S Jameson; P N Baker; D J Deehan; A Port; M R Reed
Journal:  Bone Joint Res       Date:  2014-05       Impact factor: 5.853

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.